Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.66 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11610023 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL7218504 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL29766818 | 1.00 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL10340142 | 0.99 | SIGMAR1 (0.98) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL10340144 | 0.99 | SIGMAR1 (0.98) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL14809487 | 0.98 | SIGMAR1 (0.95) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL10340106 | 0.97 | SIGMAR1 (0.95) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL10340107 | 0.97 | SIGMAR1 (0.95) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL11248186 | 0.90 | SIGMAR1 (0.81) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL11457164 | 0.87 | SIGMAR1 (0.77) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0248824-B1 | USE OF CIS-N-(2 AMINOCYCLOALIPHATIC) BENZENE ACETAMIDE AND BENZAMIDE FOR THE MANUFACTURE OF ANTICONVULSANTS | THE UPJOHN COMPANY (US) | 1990-01-17 | — | — | EP | claimed |
| US-4831167-A | HYDROGENATION, SALT FORMATION | KALI-CHEMIE PHARMA GMBH (DE) | 1989-05-16 | — | — | US | claimed |
| US-4801604-A | REDUCED ANALGESIC PROPERTIES | THE UPJOHN COMPANY (US) | 1989-01-31 | — | — | US | claimed |
| EP-0248824-A1 | Use of CIS-N-(2 Aminocycloaliphatic) benzene acetamide and Benzamide for the manufacture of anticonvulsants. | UPJOHN CO (US) | 1987-12-16 | — | — | EP | claimed |
| EP-0222533-A1 | Cis-N-[(2-aminocycloaliphatic)benzene acetamide and -benzamide anticonvulsants | THE UPJOHN COMPANY (US) | 1987-05-20 | — | — | EP | claimed |
| WO-1987002584-A1 | CIS-N-(2-AMINOCYCLOALIPHATIC)BENZENE ACETAMIDE AND -BENZAMIDE ANTICONVULSANTS | THE UPJOHN COMPANY (US) | 1987-05-07 | — | — | WO | claimed |
| US-10815192-B2 | U-47700 immunoassay | RANDOX LABORATORIES LTD. (IE) | 2020-10-27 | — | — | US | disclosed |
| EP-3366706-B1 | U-47700 IMMUNOASSAY | RANDOX LABORATORIES LTD (GB) | 2020-10-21 | — | — | EP | disclosed |
| US-6656930-B2 | Treatment of central nervous system (CNS) dysfunctions, neurodegenerative diseases and neurotoxic injury following hypoxia, anoxia or ischemia of stroke, cardiac arrest or perinatal asphyxia; antipsychotic and -convulsant agents | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-02 | — | — | US | disclosed |
| US-6310064-B1 | ADMINISTERING TO TREAT CEREBRAL ISCHEMIA OR A PSYCHOTIC DISORDER | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE OF DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-10-30 | — | — | US | disclosed |
| US-5958920-A | ANTICONVULSANTS, ANTIISCHEMIC AGENTS, BRAIN DISORDERS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-28 | — | — | US | disclosed |
| US-5856318-A | Nitrogen-containing cyclohetero cyclo-heteroaminoaryl derivatives for CNS disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-01-05 | — | — | US | disclosed |
| US-5739158-A | Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-04-14 | — | — | US | disclosed |
| US-4179501-A | Analgesic N-(2-aminocycloaliphatic)azidobenzamides | THE UPJOHN COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4153717-A | 260/332.2 R | THE UPJOHN COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4152459-A | Analgesic N-2-(aminocycloaliphatic)-hydroxy, alkoxy and (allylic)alkenyloxy-benzamides | THE UPJOHN COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4152459-A | Analgesic N-2-(aminocycloaliphatic)-hydroxy, alkoxy and (allylic)alkenyloxy-benzamides | THE UPJOHN COMPANY (US) | 1979-05-01 | — | — | US | disclosed |
| US-4148914-A | Analgesic N-(2-aminocyclo aliphatic)cyanobenzamides | THE UPJOHN COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4148914-A | Analgesic N-(2-aminocyclo aliphatic)cyanobenzamides | THE UPJOHN COMPANY (US) | 1979-04-10 | — | — | US | disclosed |
| US-4098904-A | ANALGESIC N-(2-AMINOCYCLOALIPHATIC)BENZAMIDES | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815192-B2 | U-47700 immunoassay | UNC93B1, DPY30, CCNY | SIGMAR1 3414/4885CYP3A4 3212/4885CYP2D6 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.